Skip to main navigation Skip to search Skip to main content

Control of Type I Error Rates for Oncology Biomarker Discovery with High-Throughput Platforms

  • SUNY Buffalo

Research output: Chapter in Book/Report/Conference proceedingChapterpeer-review

Abstract

This chapter provides an overview of the genetic and proteomic high-throughput platforms and the statistical methods used to evaluate molecular biomarkers for cancer diagnosis. Commonly, these experimental platforms are used in cancer diagnosis where the biomarkers can be used to determine cancer subtypes and thus potential treatments. Because of the large amount of data from these platforms, accurate testing methods are necessary. In this chapter, we highlight the statistical methods used to evaluate each potential biomarker and limit the number of false positives under a specific error rate.

Original languageEnglish
Title of host publicationStatistical Diagnostics for Cancer
Subtitle of host publicationAnalyzing High-Dimensional Data
PublisherWiley-VCH
Pages1-26
Number of pages26
Volume3
ISBN (Print)9783527332625
DOIs
StatePublished - Apr 8 2013

Keywords

  • Complementary DNA (cDNA)
  • DNA methylation
  • False discovery rate (FDR)
  • Messenger RNA (mRNA)
  • Partial deviance (PD)
  • Proteomic high-throughput platforms

Fingerprint

Dive into the research topics of 'Control of Type I Error Rates for Oncology Biomarker Discovery with High-Throughput Platforms'. Together they form a unique fingerprint.

Cite this